GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Alimera Sciences Inc (NAS:ALIM) » Definitions » Beneish M-Score

Alimera Sciences (Alimera Sciences) Beneish M-Score

: -0.87 (As of Today)
View and export this data going back to 2010. Start your Free Trial

The zones of discrimination for M-Score is as such:

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator.
An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Warning Sign:

Beneish M-Score -0.87 higher than -1.78, which implies that the company might have manipulated its financial results.

The historical rank and industry rank for Alimera Sciences's Beneish M-Score or its related term are showing as below:

ALIM' s Beneish M-Score Range Over the Past 10 Years
Min: -3.58   Med: -2.64   Max: 2.16
Current: -0.87

During the past 13 years, the highest Beneish M-Score of Alimera Sciences was 2.16. The lowest was -3.58. And the median was -2.64.


Alimera Sciences Beneish M-Score Historical Data

The historical data trend for Alimera Sciences's Beneish M-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Alimera Sciences Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Beneish M-Score
Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -2.96 -2.95 -2.61 -3.42 -0.87

Alimera Sciences Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Beneish M-Score Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -3.42 -3.68 -1.56 -0.72 -0.87

Competitive Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Alimera Sciences's Beneish M-Score, along with its competitors' market caps and Beneish M-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Alimera Sciences Beneish M-Score Distribution

For the Drug Manufacturers industry and Healthcare sector, Alimera Sciences's Beneish M-Score distribution charts can be found below:

* The bar in red indicates where Alimera Sciences's Beneish M-Score falls into.



Alimera Sciences Beneish M-Score Calculation

The M-score was created by Professor Messod Beneish. Instead of measuring the bankruptcy risk (Altman Z-Score) or business trend (Piotroski F-Score), M-score can be used to detect the risk of earnings manipulation. This is the original research paper on M-score.

The M-Score Variables:

The M-score of Alimera Sciences for today is based on a combination of the following eight different indices:

M=-4.84+0.92 * DSRI+0.528 * GMI+0.404 * AQI+0.892 * SGI+0.115 * DEPI
=-4.84+0.92 * 1.1807+0.528 * 0.9848+0.404 * 2.9193+0.892 * 1.4919+0.115 * 0.576
-0.172 * SGAI+4.679 * TATA-0.327 * LVGI
-0.172 * 0.8017+4.679 * 0.013412-0.327 * 0.4104
=-0.87

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Dec23) TTM:Last Year (Dec22) TTM:
Total Receivables was $34.55 Mil.
Revenue was 26.306 + 23.364 + 17.538 + 13.546 = $80.75 Mil.
Gross Profit was 22.68 + 20.606 + 15.113 + 11.518 = $69.92 Mil.
Total Current Assets was $52.42 Mil.
Total Assets was $153.52 Mil.
Property, Plant and Equipment(Net PPE) was $3.59 Mil.
Depreciation, Depletion and Amortization(DDA) was $8.75 Mil.
Selling, General, & Admin. Expense(SGA) was $46.48 Mil.
Total Current Liabilities was $21.91 Mil.
Long-Term Debt & Capital Lease Obligation was $64.49 Mil.
Net Income was -3.781 + -1.354 + -10.029 + -4.968 = $-20.13 Mil.
Non Operating Income was 0.256 + -1.085 + -7.102 + 0.001 = $-7.93 Mil.
Cash Flow from Operations was 3.77 + -9.826 + -5.996 + -2.209 = $-14.26 Mil.
Total Receivables was $19.61 Mil.
Revenue was 14.029 + 13.598 + 14.604 + 11.898 = $54.13 Mil.
Gross Profit was 11.904 + 11.592 + 12.438 + 10.218 = $46.15 Mil.
Total Current Assets was $29.41 Mil.
Total Assets was $42.60 Mil.
Property, Plant and Equipment(Net PPE) was $3.92 Mil.
Depreciation, Depletion and Amortization(DDA) was $2.71 Mil.
Selling, General, & Admin. Expense(SGA) was $38.86 Mil.
Total Current Liabilities was $39.73 Mil.
Long-Term Debt & Capital Lease Obligation was $18.68 Mil.




1. DSRI = Days Sales in Receivables Index

Measured as the ratio of Revenue in Total Receivables in year t to year t-1.

A large increase in DSR could be indicative of revenue inflation.

DSRI=(Receivables_t / Revenue_t) / (Receivables_t-1 / Revenue_t-1)
=(34.545 / 80.754) / (19.612 / 54.129)
=0.427781 / 0.36232
=1.1807

2. GMI = Gross Margin Index

Measured as the ratio of gross margin in year t-1 to gross margin in year t.

Gross margin has deteriorated when this index is above 1. A firm with poorer prospects is more likely to manipulate earnings.

GMI=GrossMargin_t-1 / GrossMargin_t
=(GrossProfit_t-1 / Revenue_t-1) / (GrossProfit_t / Revenue_t)
=(46.152 / 54.129) / (69.917 / 80.754)
=0.85263 / 0.865802
=0.9848

3. AQI = Asset Quality Index

AQI is the ratio of asset quality in year t to year t-1.

Asset quality is measured as the ratio of non-current assets other than Property, Plant and Equipment to Total Assets.

AQI=(1 - (CurrentAssets_t + PPE_t) / TotalAssets_t) / (1 - (CurrentAssets_t-1 + PPE_t-1) / TotalAssets_t-1)
=(1 - (52.423 + 3.59) / 153.524) / (1 - (29.413 + 3.92) / 42.602)
=0.635152 / 0.217572
=2.9193

4. SGI = Sales Growth Index

Ratio of Revenue in year t to sales in year t-1.

Sales growth is not itself a measure of manipulation. However, growth companies are likely to find themselves under pressure to manipulate in order to keep up appearances.

SGI=Sales_t / Sales_t-1
=Revenue_t / Revenue_t-1
=80.754 / 54.129
=1.4919

5. DEPI = Depreciation Index

Measured as the ratio of the rate of Depreciation, Depletion and Amortization in year t-1 to the corresponding rate in year t.

DEPI greater than 1 indicates that assets are being depreciated at a slower rate. This suggests that the firm might be revising useful asset life assumptions upwards, or adopting a new method that is income friendly.

DEPI=(Depreciation_t-1 / (Depreciaton_t-1 + PPE_t-1)) / (Depreciation_t / (Depreciaton_t + PPE_t))
=(2.706 / (2.706 + 3.92)) / (8.747 / (8.747 + 3.59))
=0.408391 / 0.709005
=0.576

Note: If the Depreciation, Depletion and Amortization data is not available, we assume that the depreciation rate is constant and set the Depreciation Index to 1.

6. SGAI = Sales, General and Administrative expenses Index

The ratio of Selling, General, & Admin. Expense(SGA) to Sales in year t relative to year t-1.

SGA expenses index > 1 means that the company is becoming less efficient in generate sales.

SGAI=(SGA_t / Sales_t) / (SGA_t-1 /Sales_t-1)
=(46.476 / 80.754) / (38.858 / 54.129)
=0.575526 / 0.717878
=0.8017

7. LVGI = Leverage Index

The ratio of total debt to Total Assets in year t relative to yeat t-1.

An LVGI > 1 indicates an increase in leverage

LVGI=((LTD_t + CurrentLiabilities_t) / TotalAssets_t) / ((LTD_t-1 + CurrentLiabilities_t-1) / TotalAssets_t-1)
=((64.489 + 21.913) / 153.524) / ((18.683 + 39.732) / 42.602)
=0.562791 / 1.37118
=0.4104

8. TATA = Total Accruals to Total Assets

Total accruals calculated as the change in working capital accounts other than cash less depreciation.

TATA=(IncomefromContinuingOperations_t - CashFlowsfromOperations_t) / TotalAssets_t
=(NetIncome_t - NonOperatingIncome_t - CashFlowsfromOperations_t) / TotalAssets_t
=(-20.132 - -7.93 - -14.261) / 153.524
=0.013412

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator. An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Alimera Sciences has a M-score of -0.87 signals that the company is likely to be a manipulator.


Alimera Sciences Beneish M-Score Related Terms

Thank you for viewing the detailed overview of Alimera Sciences's Beneish M-Score provided by GuruFocus.com. Please click on the following links to see related term pages.


Alimera Sciences (Alimera Sciences) Business Description

Traded in Other Exchanges
Address
6310 Town Square, Suite 400, Alpharetta, GA, USA, 30005
Alimera Sciences Inc is a commercial-stage pharmaceutical company developing and commercializing ILUVIEN for the treatment of diabetic macular edema (DME), a leading cause of blindness, and outside the U.S. for non-infectious uveitis affecting the posterior segment of the eye (NIU-PS). ILUVIEN is a sustained-release intravitreal implant that enables patients to maintain vision longer, and importantly, with fewer injections. The company commercializes ILUVIEN in the U.S., Europe, China and the Middle East.
Executives
Margaret Pax director 6310 TOWN SQUARE, SUITE 400, ALPHARETTA GA 30005
John Snisarenko director C/O ALIMERA SCIENCES, INC., 6120 WINDWARD PARKWAY, SUITE 290, ALPHARETTA GA 30005
Pizzo Peter J. Iii director 6120 WINDWARD PARKWAY, SUITE 290, ALPHARETTA GA 30005
Erin Parsons director 97 WILLISTON RD, BROOKLINE MA 02445
Caligan Partners Lp 10 percent owner 515 MADISON AVENUE, 8TH FLOOR, NEW YORK NY 10022
Ross D Demont director 51 PICKWICK ROAD, NEWTON MA 02465
C. Daniel Myers other: Chairman Emeritus 6120 WINDWARD PARKWAY, SUITE 290, ALPHARETTA GA 30005
David Edward Johnson 10 percent owner 590 MADISON AVENUE, NEW YORK NY 10022
Velan Capital Master Fund Lp 10 percent owner 1055B POWERS PLACE, ALPHARETTA GA 30009
Velan Capital Management Llc 10 percent owner 1055B POWERS PLACE, ALPHARETTA GA 30009
Velan Capital Holdings Llc 10 percent owner 1055B POWERS PLACE, ALPHARETTA GA 30009
Adam Morgan director 1055B POWERS PLACE, ALPHARETTA GA 30009
Velan Capital Investment Management Lp 10 percent owner 1055B POWERS PLACE, ALPHARETTA GA 30009
Velan Capital Spv I Llc 10 percent owner 1055B POWERS PLACE, ALPHARETTA GA 30009
Balaji Venkataraman 10 percent owner FIRST HORIZON PHARMACEUTICAL CORP, 660 HEMBREE PKWY STE 106, ROSWELL GA 30076

Alimera Sciences (Alimera Sciences) Headlines